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Increasing evidence suggests that oxidative stress is intimately associated with Alzheimer disease pathophysiology. Nucleic acids (nuclear
DNA, mitochondrial DNA, and RNA) are one of the several cellular macromolecules damaged by reactive oxygen species, particularly the
hydroxyl radical. Because neurons are irreplaceable and survive as long as the organism does, they need elaborate defense mechanisms to ensure
their longevity. In Alzheimer disease, however, an accumulation of nucleic acid oxidation is observed, indicating an increased level of oxidative
stress and/or a decreased capacity to repair the nucleic acid damage. In this review, we present data supporting the notion that mitochondrial and
metal abnormalities are key sources of oxidative stress in Alzheimer disease. Furthermore, we outline the mechanisms of nucleic acid oxidation
and repair. Finally, evidence showing the occurrence of nucleic acid oxidation in Alzheimer disease will be discussed.
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Alzheimer disease (AD) is a progressive, degenerative brain
disorder resulting in cognitive and behavioral decline and is the
leading cause of dementia in the Western world. Two patho-
logical hallmarks are observed in AD patients at autopsy:
intracellular neurofibrillary tangles (NFT) and extracellular
senile plaques in the neocortex, hippocampus, and other sub-
cortical regions of the brain essential for cognitive function [1].
NFT are formed from paired helical filaments composed of
neurofilaments and hyperphosphorylated tau protein [2]. In turn,
plaque cores are formed mostly from deposition of amyloid-β
peptide that results from the cleavage of the amyloid-β protein
precursor (AβPP).
Although the etiology of AD remains largely unclear, there is
accumulating evidence suggesting that oxidative stress occurs
before the onset of symptoms in AD and such oxidative changes
are pervasive throughout the body, being detected peripherally
[3–6] as well as being associated with the vulnerable regions of
the brain affected in disease [7–10]. Indeed, oxidativelymodified
products of nucleic acids (e.g., 8-hydroxydeoxyguanosine, 8-
hydroxyguanosine) and proteins (e.g., 3-nitrotyrosine, protein
carbonyls), as well as products of lipid peroxidation (e.g., 4-
hydroxynonenal, F2-isoprostane, malondialdehyde) and glycox-
idation (e.g., carboxymethyllysine, pentosidine), are known as
markers of oxidative damage. Several markers among them have
been demonstrated in the affected lesions in the postmortem brain
tissue or premortem cerebrospinal fluid (CSF), plasma, serum,
and urine from the patients with these diseases [11,12]. Most
recently there have been multiple studies showing that lipid
peroxidation, protein oxidation, and nucleic acid oxidation occur
in mild cognitive impairment (MCI), which possibly represents a
prodromal stage of AD [13–17]. The increased levels of oxi-
dative damage in neurodegenerative conditions are often accom-
panied by reduced levels of antioxidant defense mechanisms in
the subjects [18,19]. Remarkably, a number of known genetic and
environmental factors of the neurodegenerative diseases, namely
disease-specific gene mutations, risk-modified gene polymorph-
isms, and risk-modified lifestyle factors, are closely associated
with oxidative damage [12,18,20], which implicates a pathogenic
role of oxidative damage in the process of neurodegeneration.
Chronic exposure to the damaging effects of reactive oxygen
species (ROS), which are mainly formed in mitochondria during
normal cellular metabolism, is considered a major contributor to
the aging process [21]. The effects of ROS are believed to be
especially devastating to postmitotic tissues because the dam-
aged cells cannot be replaced by intact ones. Oxidative modi-
fications of RNA, nuclear DNA (nDNA) and, particularly,
mitochondrial DNA (mtDNA), are thought to play a key role in
the selective neuronal loss associated with mammalian aging
and neurodegeneration [9,22–24]. Because of the proximity toROS, lack of protective histones, and limited repair mechanisms
[21], mtDNA is highly susceptible to oxidative damage. Damage
to mtDNA could potentially result in bioenergetic dysfunction
and consequently to aberrant nerve functions.
Here we will present data supporting the notion that mito-
chondrial and metal abnormalities are key sources of oxidative
stress in AD. This article also provides an overview of nucleic
acid oxidation and repair mechanisms. Finally, data from the
literature demonstrating the occurrence and accumulation of
damaged nucleic acids in AD are discussed.
Main sources of oxidative stress in Alzheimer disease
Mitochondria
Mitochondria are essential organelles for neuronal function
because the limited glycolytic capacity of these cells makes
them highly dependent on aerobic oxidative phosphorylation
for their energetic needs. However, oxidative phosphorylation is
a major source of endogenous toxic free radicals, including
hydrogen peroxide (H2O2), hydroxyl (·OH), and superoxide
(O2·−), that are products of normal cellular respiration [25].
With inhibition of the electron transport chain, electrons
accumulate in complex I and coenzyme Q, from which they can
be donated directly to molecular oxygen to give O2
−· that can be
detoxified by the mitochondrial manganese superoxide dismutase
to give H2O2 that, in turn, can be converted to H2O by glutathione
peroxidase. However, O2·− in the presence of nitric oxide (NO·),
formed during the conversion of arginine to citrulline by nitric
oxide synthase, can generate peroxynitrite (ONOO−) and lead to
protein modification [26]. Furthermore, H2O2 in the presence of
reduced transition metals can be converted to toxic ·OH via
Fenton and/or Haber Weiss reactions, a process that we have
specifically localized to neurofibrillary pathology in AD [27].
Inevitably, if the amount of free radical species overwhelms the
capacity of neurons to counteract these harmful species, oxidative
stress occurs, followed by mitochondrial dysfunction and
neuronal damage. Reactive species generated by mitochondria
have several cellular targets, includingmitochondrial components
themselves (lipids, proteins, and DNA).
In addition to the key role of mitochondria in the maintenance
of cell energy and generation of free radicals, these organelles
are also involved in cell death pathways, namely apoptosis.
There are three main apoptotic pathways leading to the acti-
vation of caspases, which converge onto mitochondria and are
mediated throughmembers of the Bcl-2 family such as Bid, Bax,
and Bad [28]. The end result of each pathway is the cleavage of
specific cellular substrates, resulting in the morphological and
biochemical changes associated with the apoptotic phenotype.
The first of these depends on the participation of mitochondria
(mitochondrial pathway), the second involves the interaction of
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third is triggered under conditions of endoplasmic reticulum
(ER) stress (ER-specific pathway) [29]. Although a number of
apoptosis-related proteins are increased in AD [30,31], it is
unlikely that this leads to rapid cell death [32,33].
Previous studies from our laboratory show that the neurons
showing increased oxidative damage in AD also possess striking
and significant increases in mtDNA, cytochrome oxidase, and
lipoic acid [34,35]. Surprisingly, much of the mtDNA, cyto-
chrome oxidase, and lipoic acid is found in the neuronal
cytoplasm and, in the case of mtDNA and lipoic acid, in vacuoles
associated with lipofuscin.We also observed an overall reduction
in microtubules in AD compared to controls [36]. Altogether
these data indicated that the abnormal mitochondrial turnover, as
indicated by increased perikaryal mtDNA and mitochondrial
protein accumulation in the face of reduced numbers of
mitochondria, could be due to a defective microtubule system
resulting in deficient mitochondrial transport. In other studies, we
analyzed the ultrastructural features of vascular lesions and
mitochondria in brain vascular wall cells from human AD, YAC,
and C57B6/SJL transgenic positive (Tg(+)) mice overexpressing
AβPP. We observed a higher degree of amyloid-β deposition,
oxidative stress markers, mtDNA deletion, and mitochondrial
structural abnormalities in the vascular walls of human AD,
YAC, and C57B6/SJL Tg(+) mice compared to the respective
controls [37,38]. All the abnormalities observed occur before
neuronal degeneration and amyloid deposition [39,40].
Overall, these results indicate a clear involvement of oxidative
stress, mitochondria dysfunction, and neuronal damage/death
during the evolution of AD. In fact, an intricate interorganelle
cross talk was previously suggested by Ferri and Kroemer [28],
who reviewed the participation of distinct organelles, namely the
nuclei, lysosomes, ER, and Golgi, in the release of death signals
that converged in mitochondria, the central executioners. To
obtain more information on the involvement of mitochondria in
AD pathophysiology please see the review articles by Moreira
et al. [41,42] and Zhu et al. [43].
Redox-active metals
The loss of homeostasis of iron and copper in the brain is
accompanied by severe neurological consequences. In patients
with AD, overaccumulation of iron in the hippocampus, cerebral
cortex, and basal nucleus of Meynert colocalizes with AD
lesions, senile plaques, and NFT [27,44]. Iron is an important
cause of oxidative stress in AD because it is found in consid-
erable amounts in the AD brain [45] and, as a transition metal, is
involved in the formation of ·OH via the Fenton reaction [46].
Furthermore, it has been reported that amyloid-β itself is a
substrate for ·OH [44]. Amyloid-β extracted from postmortem
AD brains presents oxidative modifications such as carbonyl
adduct formation, histidine loss, and dityrosine cross-linking,
making this protein less water soluble and less susceptible to
degradation by the proteases [44,47,48]. Furthermore, it has
been reported that amyloid-β deposition and AβPP cleavage
and synthesis are promoted by the presence of iron [49], like-
ly consequential of oxidative stress-mediated events [50,51].Huang and collaborators [52] presented in vitro evidence that
trace levels of zinc, copper, and iron are initiators of an amyloid-
β1–42-mediated seeding process and amyloid-β oligomerization
and these effects were abolished by chelation of trace metals.
Interestingly, the in vitro toxicity of amyloid-β is also abolished
by pretreatment with metal chelators [53]. Data from our
laboratory and others also indicate that heme oxygenase-1 (HO-
1) is induced in AD brains [54,55]. HO-1 catalyzes the con-
version of heme to biliverdin and iron. Biliverdin, in turn, is
reduced to bilirubin, an antioxidant. Because HO-1 is induced in
proportion to the level of heme [56], the induction of HO-1
suggests that there may be an abnormal turnover of heme in AD.
This idea is consistent with the mitochondrial abnormalities
associated with AD because it is well known that many heme-
containing enzymes are found in mitochondria. As previously
discussed, our ultrastructural studies suggest a high rate of
mitochondrial turnover and redox activity in the residual body of
lipofuscin [34,35]. In turn, the increase in heme induces
synthesis of more HO-1, suggesting that mitochondrial turnover
promotes oxidative stress via increase of redox-active iron [57].
Recently, we reported that ribosomal RNA (rRNA) provides
a binding site for redox-active iron and serves as a redox center
within the cytoplasm of vulnerable neurons in AD in advance of
the appearance of morphological change indicating neurode-
generation [57]. Furthermore, we observed that oxidized nucleic
acids are commonly observed in the cytoplasm of the neurons
that are particularly vulnerable to degeneration in AD [10]. 8-
Hydroxyguanosine (8OHG), a marker of nucleic acid oxidation,
is likely to form at the site of ·OH production, a process
dependent on redox-active metal-catalyzed reduction of H2O2
together with cellular reductants such as ascorbate or O2·−.
Interestingly, the levels of 8OHG are inversely related to the
amount of amyloid-β present as extracellular deposits [10] or
intracellular oligomeric forms [58], suggesting a complex inter-
play between amyloid-β and redox metal activity that may
be critical to metal dynamics within the neuronal cytoplasm
[59,60]. A possible key element in these dynamics is mito-
chondria in the neuronal cell body.
Copper can also participate in the Fenton reaction to generate
ROS [61,62]. Although conflicting results exist concerning the
amount of copper and the formation of senile plaques [63,64],
there is accumulating evidence that both iron and copper in their
redox-competent state are bound to NFT and amyloid-β depos-
its [27,45,46]. However, a recent study reported that cognitive
decline correlates with low plasma concentrations of copper in
patients with mild to moderate AD [65]. To obtain more infor-
mation on the involvement of metals in AD pathophysiology,
please see the review articles by Adlard and Bush [66] and Zhu
et al. [43].
DNA oxidation and repair
ROS-mediated oxidative injury can result in DNA modifica-
tions, including base alterations, single and double strand
breaks, sister chromatid exchanges, and DNA–protein cross-
links [67,68]. The hydroxyl radical plays a major role in DNA
oxidation. Because the copper ion, through the Fenton reaction,
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likely that ·OH is formed in close proximity to the DNA target
[69]. Additionally, ROS attack of DNA can lead to the
production of more than 20 oxidized base adducts [70,71],
changes that are more subtle and require close analysis of DNA
molecules to determine alterations. DNA bases may also be
modified by neurotoxic markers of lipid peroxidation including
4-hydroxynonenal and acrolein, leading to formation of bulky
exocyclic adducts. Formation of modified DNA bases could
result in alterations in replication of DNA or inappropriate base
pairing producing mutations that could lead to altered protein
synthesis. Indeed, it has been reported that ·OH reacts with
purines to form mutagenic 8-hydroxypurine and putatively
nonmutagenic formamidopyrimidine lesions. The formamido-
pyrimidine lesions inhibit DNA synthesis, likely modulating the
mutagenic potential of the 8-hydroxypurine lesions, which
would suggest that the ratio of these oxidized bases is bio-
logically important [72–74]. Because it has the lowest oxidation
potential of the four DNA bases, guanine is the most readily
oxidized base through free radical attack of C8 leading to the
formation of 8OHG under elevated oxygen tension and 2,6-
diamino-4-hydroxy-5-formamidopyrimidine (fapyguanine)
under conditions of reduced oxygen tension [68,70,75]. Be-
cause of the ease of oxidation and the presence of oxygen,
8OHG is the most commonly studied marker of DNA oxidation
and is measured using either enzymatic digestion of DNA and
high-pressure liquid chromatography or acid hydrolysis of
DNA followed by derivatization and analysis using gas chro-
matography. Previous studies show that 8OHG is increased in
the aging brain [76–78]. Although present at lower absolute
concentrations compared to 8OHG, fapyguanine is of impor-
tance in that it is formed from radical attack of C8 of guanine
followed by opening of the ring under conditions of low oxygen
tension. Similar adducts, 8-hydroxyadenine and fapyadenine,
are formed during radical attack of C8 of adenine. Measurement
of both adducts for a particular base provides information
regarding the conditions under which adducts were formed.
mtDNA oxidation, especially 8OHG, is of a much greater
magnitude than nDNA. nDNA gains some protection from his-
tones and morphologically is not close to large oxidant gen-
eration. In contrast, mtDNA does not have protective histones, is
in close proximity to oxidant generation, may not have a rich
antioxidant system, and has relatively limited DNA repair
capacity, which may account for some of its vulnerability to
oxidation. The accumulation of oxidatively modified nDNA and
mtDNA results from an imbalance between the rate of oxidation
and DNA repair mechanisms.
To counteract the multiple factors causing DNA damage,
three DNA repair pathways have evolved. The most prominent
repair pathways are base excision repair (BER), nucleotide
excision repair, and mismatch repair. BER is characterized by
the excision of nucleic acid base residues in the free form that
contain lesions including oxidative damage, alkylating adducts,
and deamination products. Nucleotide excision repair removes
damaged nucleotides as part of fragments up to 30 bases in
length. Mismatch repair corrects single misrepaired nucleotides
and smaller loops.BER is the main pathway to repair oxidative DNA damage.
The first step in BER is the removal of the damaged base by
substrate-specific DNA glycosylases. These enzymes catalyze
the hydrolysis of the N-glycosidic bond between the modified
base and the sugar moiety to release the base and generate an
abasic (AP) site and this site will be cleaved by an abasic lyase
or abasic endonuclease [79]. Repair can then proceed through
the short- or long-patch BER. The short patch involves the
incorporation of a single nucleotide into the gap by DNA
polymerase followed by strand ligation by DNA ligase. The
long-patch BER involves incorporation of several nucleotides,
typically 2 to 7, followed by cleavage of the resulting 5′ flap and
ligation. Mitochondria possess independent BER machinery,
the components of which are coded by nuclear genes [79].
Several DNA ligases that have both nuclear and mitochon-
drial forms have been identified. Mitochondrial (UNG1) and
nuclear (UNG2) forms of uracil-DNA glycosylase are generated
by alternative splicing and transcription from different positions
in the UNG gene [80]. Similarly, nuclear and mitochondrial
adenine-DNA glycosylases are encoded by alternatively spliced
forms of theMYH gene [81]. The oxoguanine-DNA glycosylase
(OGG) 1 is the primary enzyme for the repair of 8-oxoguanine
(8-oxoG) in both nDNA and mtDNA [82,83]. Previous studies
showed that OGG1-deficient mice exhibit only a moderately
elevated spontaneous mutation rate in nonproliferative tissues.
OGG−/−mice do not develop malignancies and show no marked
pathological changes. These animals are viable; however, their
cells, in particular liver cells, exhibit a higher steady-state level
of endogenous 8-oxoG in their genomes [82,83]. In light of the
fact that it was shown that OGG−/−mouse embryonic fibroblasts
are not deficient in the repair of 8-oxoG in the actively
transcribed DNA strand, it is likely that the increase in the
cellular level of 8-oxoG may be localized to the nontranscribed
DNA strand or regions of the genome that are not actively
transcribed [84]. In humans two distinct OGG1 isoforms are
present: α-OGG1, which localizes to the nucleus and mitochon-
dria, and β-OGG1, which localizes only to mitochondria [85].
Nei-like homologs (NEILs) are a recently identified group of
bifunctional DNA glycosylases, which are mammalian orthologs
of the Escherichia coliMutM/Nei. Both NEIL1 and NEIL2 have
a broad substrate specificity in vitro, including but not limited to
8-oxoG, 2,6-diamino-4-hydroxy-5-formamidopyrimidine, 5-
hydroxycytosine, and 5-hydroxyuracil. NEILs are localized in
the nucleus [86,87] as well as in the mitochondria [88].
The AP generated after the removal of the damaged base by
DNA glycosylase is incised by abasic endonucleases/lyases
such as exonuclease III in E. coli or APE1 in mammalian cells.
APE1 has been localized to the nucleus, the cytoplasm, and the
mitochondria, despite the lack of a classical mitochondrial
targeting sequence [89–91]. APE2 is also partly localized to the
mitochondria in HeLa cells and a putative mitochondrial
targeting sequence was found in the APE2 gene [92].
The gap generated by the cleavage of the AP is filled in by
DNA polymerases: Pol β or Pol δ/ε in the nucleus and Pol γ in
the mitochondria. Pol γ is the only DNA polymerase identified
so far in vertebrate mitochondria and functions both as the
replicative and as the repair polymerase [93].
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behind by DNA polymerases. In the nucleus, ligase I par-
ticipates in long-patch BER and ligase III participates in short-
patch BER. The human ligase III gene also encodes a mito-
chondrial variant [94,95]. The localization of ligase III protein
to mitochondria suggests, then, that this enzyme may perform
the ligation step in mitochondrial BER. Age-related changes in
BER have been intensively studied using several experimental
approaches. Measuring the levels and kinetics of AP sites after
damage of nDNA [96] showed that senescent human fibroblasts
as well as leukocytes from old donors have higher basal level of
AP sites than young cells. Upon treatment with H2O2 the level
of AP sites rose faster in young cells than in old cells, suggest-
ing a deficiency in DNA glycosylase activity [96]. Furthermore,
a significant decrease in the mitochondrial incision activity of
8-oxoG-DNA glycosylase, uracil-DNA glycosylase, and the
endonuclease III homolog was found in the brains of old mice,
whereas smaller changes were observed in nuclear incision
activity [97–99]. Similarly, a decline in cleavage activity was
observed in mitochondrial and, to a lesser extent, in nuclear
extracts from senescent human fibroblasts [100]. A different in
vitro assay measuring the repair of the synthetic DNA substrate
containing a single G:U mismatch showed a strong decline in
BER activity in brain, liver, and germ-cell nuclear extracts of
old mice [101]. Germ-cell extracts from old mice were found to
contain reduced levels of APE1, and supplementation with
purified recombinant enzyme restored the activity to a level
similar to that of the young animals [101]. Reduced abundance
of DNA polymerase β in brain extracts from mice and rats has
also been reported [101–103]. In addition to altered enzyme
activity, the mechanism for the age-related decline of BER may
lie in an altered response to DNA damage. For example, the
expression of DNA polymerase β and AP endonuclease was
induced by DNA damage in young mice, whereas aged mice
showed a lack of inducibility [104]. Furthermore, old mice and
senescent human fibroblasts were deficient in the translocation
of OGG and AP endonuclease into both their nuclei and their
mitochondria [105,106].
The inactivation or malfunction of DNA repair mechanisms
leads to the accumulation of damaged DNA that characterizes
several pathological conditions, including AD.
DNA oxidation and accumulation in Alzheimer disease
Several groups have documented the accumulation of
oxidative DNA damage during aging in the brain [107–109].
Because of the critical role of DNA in cellular function, oxidative
damage to DNA may be one of the most important factors in
neuron degeneration in AD. Lu et al. [23] found that oxidative
DNA damage accumulates preferentially in the promoter regions
of several genes involved in synaptic plasticity, vesicular trans-
port, and mitochondrial function. A differential accumulation of
oxidative DNA lesions among brain regions has also been
reported, suggesting that some areas of the brain are more prone
to oxidative DNA modifications than others [110,111].
A substantial body of evidence indicates that oxidative DNA
damage is a feature of AD in the brain as well as in peripheraltissues. Higher concentrations of oxidized pyridines and purines
were detected in lymphocytes and leukocytes of AD patients
compared with controls [6,112–114], and increased levels of
8-oxoG were observed in DNA from ventricular CSF of AD
patients [115]. Recent findings indicate increased oxidative
damage in leukocytes [6] and brain tissue [17] of subjects with
MCI, which suggests that DNAoxidationmay constitute an early
event in the progression of AD, before cytopathological
alterations, andmay contribute to the pathogenesis of the disease.
Although DNA damage is elevated in both nDNA and
mtDNA, the latter may be more easily oxidized than nDNA due
to its proximity to free radical species. Previous studies show
that there is more 8-hydroxy-2′-deoxyguanosine in mtDNA
than in nDNA and there is a significant increase in aged subjects
compared to younger subjects [116,117]. More recently, Wang
and collaborators [118] reported that the levels of multiple
oxidized bases in AD brain specimens were significantly higher
in frontal, parietal, and temporal lobes compared to control
subjects and that mtDNA had approximately 10-fold higher
levels of oxidized bases than nDNA. These data are consistent
with higher levels of oxidative stress in mitochondria. Without
efficient repair ability in the brain in AD, mutations in nDNA
and mtDNA may result in neuron death through defects in
oxidative phosphorylation [25,115,119].
Additionally, a higher incidence of single- and double-strand
breaks and alkali-labile DNA lesions has been detected in the AD
cerebral cortex [120–122]. On the other hand, both increased
and unaltered 8-hydroxy-2′-deoxyguanosine levels have been
reported in AD brain nucleus samples [119,123,124]. A complex
study has reported augmented degrees of some other (8-OH-
adenine, 8-OH-guanine, and thymine glycol), but not all oxidized
bases in the AD cerebral cortex [125]. The amounts of multiple
oxidized bases of both nDNA and mtDNA were greater in the
frontal, parietal, and temporal lobes in AD compared with the
controls [118]; and, as expected, DNA from the temporal lobe
displayed the most oxidative damage, whereas the cerebellum
was only slightly affected, and mtDNA had 10-fold higher levels
of oxidized bases. Increased mtDNA damage in AD is also
associated with reduced mtDNA content, cytochrome oxidase
protein levels [126], heteroplasmic mtDNA control-region
mutations, and a reduction in the mtDNA L-strand transcript
and in the mtDNA/nDNA ratio [127].
The accumulation of DNA damage in AD patients poses the
question of whether the disease is accompanied by a deficiency
in DNA repair. Several groups have tested this hypothesis, with
inconclusive results. Some studies confirmed a decreased DNA
repair efficiency [128–130], whereas others did not [131,132].
RNA oxidation and repair
Recent progress in genetics reveals an expanding universe of
RNA beyond its classical function as intermediate for protein
synthesis in the “central dogma” that describes transcription
from DNA to messenger RNA (mRNA) and translation from
mRNA to proteins. It is now evident that only a minority of
genetic transcripts (2–3% in the human) code for proteins.
Noncoding RNA (ncRNA), rather than being “junk,” not only
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in regulating the timing and rate of gene expression [133–135].
Of particular interest, the complexity of an organism is poorly
correlated with its number of protein-coding genes, but highly
correlated with its number of ncRNAs [136]. Furthermore, the
increasing variety of ncRNAs being identified in the CNS
suggests a strong connection between the biogenesis, dynamics
of action, and combinational regulatory potential of ncRNAs
and the complexity of the CNS [134,135]. Therefore, further
advances in studies on the mechanisms and consequences of
RNA damage and its surveillance may have a significant impact
on the understanding of the pathophysiology of currently
unresolved complex diseases including neurodegenerative and
psychiatric diseases [134,136,137].
Because RNA is mostly single-stranded and its bases are not
protected by hydrogen bonding and probably less protected by
specific proteins, RNA may be more susceptible to oxidative
insults than DNA [9,138,139]. This is a reasonable proposition
given also the relative cellular abundance of RNA and the
subcellular distribution of RNA that locates in the vicinity of the
source of ROS, mitochondria [9]. Indeed, greater oxidation in
RNA than in DNA was demonstrated in several experimental
studies on isolated DNA and RNA [140] as well as on non-
neuronal cell lines and tissue, namely, human leukocytes [141],
human skin fibroblasts [142], and human lung epithelial cells
[143].
Although more than 20 different types of oxidatively altered
purine and pyrimidine bases have been detected in nucleic acids
[144–147], guanine is the most reactive of the nucleic acid bases
[148]. Therefore, the oxidized base 8OHG is the most abundant
among the oxidized bases [138]. The 8OHG-containing nu-
cleoside can be formed in RNA by direct oxidation of the base
and also by the incorporation of the oxidized base from the
cytosolic pool into RNA through the normal action of RNA
polymerase [146,148]. Not only 8OHG but also 8-hydroxyade-
nosine, 5-hydroxycytidine, and 5-hydroxyuridine have been
identified in oxidized RNA [148], which may have altered
pairing capacity and thus be at the origin of erroneous produc-
tion. Indeed, 8OHG can pair with both adenine and cytosine,
and thus the oxidized RNA compromises the accuracy of trans-
lation [146,149].
The biological consequences of oxidatively damaged mRNA
species have been investigated in vitro by expressing them in cell
lines. Oxidized mRNAs lead to loss of normal protein level and
protein function and potentially produce defective proteins
leading to protein aggregation, a common feature of neurode-
generative diseases [150]. Recently it has been shown that the
translation of oxidized mRNA in cell lines causes the accumula-
tion of short polypeptides, which is a result of premature
termination of the translation process of the oxidized mRNA and/
or the proteolytic degradation of the modified protein containing
the translation errors due to the oxidized mRNA [151].
Additionally, it has also been shown that the oxidative damage
to E. coli 16S rRNA results in the formation of short com-
plementary DNA (cDNA) [152]. Also the biological conse-
quences of ribosomal oxidation have been investigated in vitro
using a translation assay with oxidized ribosomes from rabbitreticulocytes and showed a significant reduction of protein
synthesis [57]. Previous studies demonstrate that the brains of
subjects with AD and MCI present ribosomal dysfunction asso-
ciated with oxidative RNA damage [14,153]. Isolated polyribo-
some complexes fromAD andMCI brains show decreased rate of
protein synthesis without alteration in the polyribosome content.
Decreased rRNA and transfer RNA (tRNA) levels and increased
8OHG in the total RNA pool, especially in rRNA, are
accompanied by the ribosomal dysfunction, whereas there is no
alteration in the level of initiation factors [14]. These findings
have indicated that RNA oxidation has detrimental effects on
cellular function whether the damaged RNA species are coding
for proteins (mRNA) or performing translation (rRNA and
tRNA). Recently, Shan and collaborators [154] used cortical
primary dissociated cultures to investigate the relationship
between RNA oxidation and neuronal degeneration induced by
various oxidative insults such as H2O2, glutamate, and amyloid-β
peptide. The authors observed that RNA oxidation was an early
event far preceding cell death, not merely a consequence of dying
cells. RNA oxidation occurred primarily in a distinct group of
neurons that died later. Identification of oxidized RNA species
revealed that significant amounts of mRNAs were oxidized and
that some mRNA species were more susceptible to oxidative
damage. Consequently, the levels of proteins corresponding to the
oxidized mRNA species were significantly decreased [154]. It is
noteworthy that studies on some anti-cancer agents have shown
that RNA damage can lead to cell-cycle arrest and cell death,
much as DNA damage does. RNA damage may cause cell death
via involvement of a p53-dependent mechanism associated with
inhibition of protein synthesis or a p53-independent mechanism
different from inhibition of protein synthesis [155].
Degradation of RNA plays a central role in RNA metabolism
and damaged RNA can be removed through degradation by
ribonucleases (RNases), but selective degradation activity for
oxidized RNA has not been established for known RNases
[139,156]. Oxidative stress induces cytoplasmic mRNA proces-
sing bodies (P-bodies), the site of active degradation of mRNA
[157]. In contrast to mRNAs with rapid turnover, stable RNAs,
consisting primarily of rRNAs and tRNAs and encompassing as
much as 98% of total cellular RNA, may be protected against
RNase action by tertiary structure, assembly into a ribonucleo-
protein complex, or even blocking the RNA's 3′ terminus [156].
Until recently, it has been considered that damaged RNA
may be only degraded rather than repaired. However, Aas et al.
[158] have suggested that the cells have at least one specific
mechanism to repair RNA damage, indicating that cells may
have a greater investment in the protection of RNA than
previously suspected [138,155,159]. Indeed, alkylation damage
in RNA is repaired by the enzyme AlkB in E. coli and the
related protein in humans [158]. AlkB and its homolog hABH3
cause hydroxylation of the methyl group on damaged RNA
bases and thus directly reverse alkylation damage. AlkB and
hABH3, but not hABH2, repair RNA, as AlkB and hABH3
prefer single-stranded nucleic acids, whereas hABH2 acts more
efficiently on double-stranded DNA [158].
Because oxidation of nucleotides can occur in the cellular
nucleotide pool and the oxidized nucleotide can be incorporated
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of the oxidized nucleotide is involved in coping with nucleic acid
damage [138,139]. MutT protein in E. coli and its mammalian
homolog MutT homolog 1 (MTH1) and Nudix type 5 (NUDT5)
proteins participate in this error-avoiding mechanism by
hydrolyzing the oxidized nucleoside diphosphates and/or tripho-
sphates to the monophosphates [146,149,160]. Indeed, the
increase in the production of erroneous proteins by oxidative
damage is 28-fold over the wild-type cells in E. coli MutT-
deficient cells, which is reduced to 1.2- or 1.4-fold by the
expression of MTH1 or NUDT5, respectively [146]. Corre-
spondingly, MTH1 deficiency augments the RNA oxidation
induced by kainic acid treatment in MTH1-null mouse [161]. An
increased expression of humanMTH1 in the vulnerable neuronal
populations has been demonstrated in the postmortem brains of
AD [162], which may indicate a compensatory up-regulation of
the MTH1 against oxidative stress [160]. In addition to the
degradation activity of MTH1 and NUDT5, several enzymes
involved in nucleotide metabolism show a discriminator activity
against the oxidized nucleotides. Guanylate kinase, an enzyme
that converts GMP to GDP, is inactive on 8-OH-GMP, whereas
nucleotide diphosphate kinase, an enzyme that converts GDP to
GTP, fails to show such discriminating function [163]. Similarly,
ribonucleotide reductase, an enzyme that catalyzes reduction of
four naturally occurring ribonucleoside diphosphates, is inactive
on conversion of 8-OH-GDP to 8-OH-dGDP, which avoids
incorporation of the oxidized nucleotide into DNA synthesis
[163]. The final gatekeeper discriminating the oxidized nucleo-
tide from normal nucleotide is RNA polymerase, which incor-
porates 8-OH-GTP into RNA at a much lower rate compared to
the normal GTP incorporation [139,149].
Then, one important question is whether cells have machi-
neries against oxidatively damaged nucleotides that are contained
in RNA, because RNA can be directly oxidized even if the
incorporation of oxidized nucleotides into RNA is blocked
strictly. Recently, proteins that bind specifically to 8OHG-
containing RNA have been reported, namely, E. coli polynucleo-
tide phosphorylase (PNP) protein and human PNP [164,165] as
well as human Y-box-binding protein 1 (YB-1) [166]. The bind-
ing of the specific protein likely makes the 8OHG-containing
RNA resistant to nuclease degradation [164]. However, it has
been proposed that these proteins may recognize and discrimi-
nate the oxidized RNA molecule from normal ones, thus con-
tributing to the fidelity of translation in cells by sequestrating the
damaged RNA from the translational machinery [164,165]. The
human PNP protein binds to 8OHG-containing RNA preferen-
tially and cellular amounts of human PNP protein decrease
rapidly by exposure to agents inducing oxidative stress, whereas
amounts of other proteins in the cells do not change after the
treatments [166]. Recently, human YB-1 is demonstrated to be a
component of P-bodies, where active degradation of mRNA
occurs. YB-1 is translocated from P-bodies to stress granules
during oxidative stress, which suggests a dynamic link between
P-bodies and stress granules under oxidative stress [167].
It is possible that the RNA quality control mechanisms are
defective or inefficient in AD as well as in other neurodegen-
erative diseases. Further elucidation of the mechanisms of repairor avoidance of RNA damage and their potential role in pre-
venting human diseases might provide new approaches to a
number of unresolved issues of life science, although it has not
been the major focus in investigation for a long period [9,138].
RNA oxidation and accumulation in Alzheimer disease
Disruption of transcriptional or translational fidelity in
neurons leads to the accumulation of aberrant or misfolded
proteins and neuronal death [168,169], which suggests a role for
RNA damage in the underlying mechanisms of neurological
diseases. As previously discussed, oxidative damage to DNA has
been well studied and several classes of products are identified.
However, many fewer studies have focused on oxidative damage
to RNA and only several kinds of oxidatively modified bases in
RNA have been previously reported [144,170].
Shan et al. [150] used Northwestern blotting with a mono-
clonal anti-8OHG antibody to isolate and identify oxidized RNA
species and showed that significant amount of poly(A)+ mRNA
species were oxidized in AD brain. The oxidation to mRNAwas
further confirmed by cDNA synthesis and Southern blotting of
the immunoprecipitated mRNA species. Densitometric analysis
of the Southern blot results revealed that 30–70% of the mRNAs
from AD frontal cortices were oxidized, whereas only 2% of the
mRNAs were oxidized in age-matched normal controls [171].
Honda et al. [57] and Ding et al. [14] reported that rRNA,
extremely abundant in neurons, contained 8OHG in AD brain.
Remarkably, rRNA showed higher binding capacity to redox-
active iron than tRNA, and consequently the oxidation of rRNA
by the Fenton reaction formed 13 times more 8OHG than tRNA
[57]. Of note, both immunocytochemical studies [9,12] and
biochemical studies [14,150] revealed that the regional distribu-
tion of RNA oxidation in the brain was consistent with the
selective neuronal and vascular wall cells vulnerability. There
were increased levels of 8OHG in the hippocampus and cere-
bral neocortex in AD, whereas no alteration in the 8OHG level
was found in the cerebellum in AD compared with controls
[9,12,14,150]. Immunocytochemical approaches further enabled
confirmation that the oxidized RNAs were localized predomi-
nantly in neuronal and vascular wall (especially endothelial) cells
compared with glial cells [10,58,172]. In addition, coexistence of
RNA oxidation with mtDNA overproliferation and deletion in a
select population of vulnerable neurons and vascular wall cells
was demonstrated [173,174].
There is a considerable amount of evidence supporting early
involvement of RNA oxidation in the pathological cascade of
neurodegeneration, especially in AD. Namely, RNA oxidation
has been observed in postmortem brains of cases with early stage
AD [10,12], a presymptomatic case with familial AD mutation
[58], Down syndrome cases with early stage AD pathology [175],
and subjects with MCI [14,153]. Furthermore, there are increased
levels of oxidized RNA in CSF in cases with shorter duration of
AD as well as in AD cases with higher scores in a cognitive scale.
The early involvement of RNA oxidation in disease pathophy-
siology suggests that oxidized RNA has a key role in neuronal
degeneration and death and is not just an epiphenomenon.
Oxidized RNAs are likely degradedmore rapidly compared to the
Fig. 1. Nucleic acid oxidation and repair. ROS are produced by normal metabolism. However, during aging and in age-related neurodegenerative diseases the levels of
ROS increase and the repair mechanisms decline, leading to the oxidative lesion of several biomolecules including nuclear and mtDNA and RNA. The accumulation of
damaged nucleic acids may lead to the development of neurodegenerative conditions such as AD. Therapeutic strategies aimed at increasing the efficiency of repair
mechanisms or fighting oxidative stress could be useful in the arrest of disease progression.
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protein carbonyls, lipid peroxidation products, and glycoxidation
products are stable at the site of generation because of a cross-
link formation resistant against degradation. Therefore, when
we detect the markers by in situ approach on the tissues affected
by disease, protein carbonyls, lipid peroxidation products, or
glycoxidation products indicate a “history” of oxidative damage,
whereas RNA oxidation reflects a “steady-state balance” of the
damage [9,176]. In accordance with this concept, protein car-
bonyls and lipid peroxidation products such as 4-hydroxynonenal
and F2-isoprostane have been demonstrated in neurons of AD
brains with no predilection for pathology burden [8,47], possibly
reflecting the damage all through early and advanced stages of
neurodegeneration (“history” of the damage). These observations
contrast remarkably with the pattern of the RNA oxidation, a
“steady-state” marker, which is prominent in neurons without
pathology [10,175].
Conclusion
Oxidative damage of nucleic acids plays an important role in
aging and neurodegenerative conditions such as AD. Indeed, AD
is characterized by an accumulation of damaged DNA (nuclear
and mitochondrial) and RNA, which is positively correlated with
the increased levels of oxidative stress and, possibly, the de-
creased activity of repair mechanisms that occur in this pathology
(Fig. 1). Indeed, evidence from the literature establishes that
oxidative damage is an early event in the pathogenesis of AD,
which can serve as a therapeutic target to slow the progression
or perhaps the onset of the disease. Furthermore, particular
emphasis should be placed on the early stage involvement of
DNA and RNA oxidation in AD, which suggests a primary role
for nucleic acid oxidation in the process of neurodegeneration.
The proteins involved in nucleic acid repair pathways could
represent important therapeutic targets. Indeed, some of these
proteins are already being studied for cancer treatment. For
example, the inhibition of various proteins in the DNA repair
pathways sensitizes cancer cells to DNA-damaging agents such
as chemotherapy and/or radiation [177]. In neurodegenerative
conditions the goal of the therapeutic strategies must be the
opposite, i.e., increase the activity of proteins involved in the
repair pathway. However, before the design of new therapeuticstrategies, it is important to answer the question of how
neurodegeneration is linked to deficiencies in specific DNA
and/or RNA repair pathways. Although intensive research in the
area of DNA repair has led to rapid advances in understanding
DNA repair mechanisms and the possible role of DNA repair in
preventing cellular dysfunction and human disease, the specific
role of DNA repair in neuronal cells and in the central nervous
system is still unclear. Multidisciplinary efforts, encompassing
molecular biology, physiology, stem cell biology, and imaging
and clinical/translational approaches, are being combined to
understand how genome instability and DNA repair contribute to
neurodegenerative conditions (for more information, see [178]).
Bioinformatics can be used to analyze single-nucleotide poly-
morphisms and identify gene constellations represented in
patients with specific clinical syndromes (for more information,
see [178]). Eventually, this approach might be developed as a
prognostic or diagnostic tool for neurodegenerative disease.
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